Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00115336 |
The purpose of this study is to compare ketorolac, a potent, non-steroidal anti-inflammatory drug (NSAID), with ibuprofen, a commonly used NSAID, for the treatment of the painful crisis of sickle cell disease (SCD).
Condition | Intervention | Phase |
---|---|---|
Hematologic Diseases Anemia, Sickle Cell |
Drug: Intravenous Ketorolac Drug: Ibuprofen |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Ketorolac Versus Ibuprofen for the Painful Crisis of Sickle Cell Disease - Southwestern Comprehensive Sickle Cell Center |
Estimated Enrollment: | 120 |
Study Start Date: | January 2005 |
Estimated Study Completion Date: | December 2008 |
Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Intravenous ketorolac and oral placebo
|
Drug: Intravenous Ketorolac
Intravenous ketorolac
|
2: Active Comparator
Intravenous placebo and oral ibuprofen
|
Drug: Ibuprofen
Ibuprofen, taken orally
|
BACKGROUND:
SCD is a common disorder among African Americans and other minority groups. It is characterized by chronic anemia and episodic vaso-occlusive crises. The most common of these crises is the painful crisis. Current treatment of the painful crisis includes rest, hydration, and analgesic medication. Morphine is the most commonly prescribed analgesic medication for moderate to severe painful episodes, but there are several side effects associated with its use, including somnolence, respiratory depression, constipation, dysphoria, and pruritus. Other analgesic medications, including NSAIDs, may improve pain control and decrease the need for morphine and other opioid drugs; however, more research is needed to confirm the benefits in individuals with SCD.
DESIGN NARRATIVE:
This study will enroll 120 children who will receive standard opioid and supportive therapy. In addition to this care, participants will be randomly assigned to receive one of the following: 1) intravenous ketorolac and oral placebo; or 2) intravenous placebo and oral ibuprofen. Outcome assessments will include the duration of hospitalization for opioid therapy; the degree of pain intensity and relief determined by validated pain scales; and the utilization of opioid medications during hospitalization. All participants will be monitored for potential adverse effects of the study medications by laboratory measurements and clinical assessments. Additionally, participants will self-report pain levels using the Oucher pain scale. Participants will be monitored for the development of adverse events, including gastrointestinal symptoms and deterioration of kidney function, as determined by daily kidney function tests including BUN, creatinine, and hematuria.
Ages Eligible for Study: | 6 Years to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
University of Texas Southwestern Medical Center | |
Dallas, Texas, United States, 75390 |
Study Chair: | Charles T. Quinn, MD | University of Texas Southwestern Medical Center |
Responsible Party: | U.T. Southwestern Medical Center Dallas ( Charles T. Quinn, M.D. ) |
Study ID Numbers: | 191, U54 HL70588 |
Study First Received: | June 21, 2005 |
Last Updated: | August 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00115336 |
Health Authority: | United States: Federal Government |
Blood Diseases Sickle Cell Anemia |
Ibuprofen Hematologic Diseases Ketorolac Anemia Anemia, Hemolytic Pain Sickle cell anemia |
Anemia, Hemolytic, Congenital Genetic Diseases, Inborn Hemoglobinopathies Hemoglobinopathy Ketorolac Tromethamine Anemia, Sickle Cell |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Cyclooxygenase Inhibitors Enzyme Inhibitors Pharmacologic Actions Analgesics, Non-Narcotic |
Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |